VCBeat Health
Contact Us
Home
China Healthcare Select
Insights
MNC China Lens
Vertical Industries
Services
Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory
About VCBeat
Why VCBeat
Log In
Home
Abbisko Therapeutics Receives $13.52M Milestone Payment from Merck for Bejemay® China First Prescription and Q1 2026 Sales Royalty
Abbisko Therapeutics Receives $13.52M Milestone Payment from Merck for Bejemay® China First Prescription and Q1 2026 Sales Royalty
Jun 09, 2026 09:00 CST Updated 09:23
Share:
